Stock Detail
ENZO BIOCHEM INC
Sector: Biotechnology
Latest Quote @ Wed May 5 06:38:05 (15 min delayed)
| N/A |
N/A |
$2.29 |
+0.04 |
1.78% |
|
Last Day's Data
| $2.29 |
$2.30 |
$0.04 |
1.78% |
0.00 |
$2.25 |
| $2.24 |
$2.19 |
58,519.00 |
90.18M |
118,873.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 2.37 |
2.33 |
2.26 |
2.22 |
2.15 |
Stock Profile
Enzo Biochem, Inc., together with its subsidiaries, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects, and other medically pertinent diagnostic information. The company's major product categories include preformatted in situ kits, preformatted microplate kits, membrane kits, labeled probes, and labeling and signaling reagents. It is also conducting research and development activities in the development of therapeutic products based on the company's technology platform of genetic modulation and immune modulation. Enzo Biochem is evaluating its proprietary gene medicine for HIV-1 infection, as well as its proprietary immune regulation medicines for hepatitis B and hepatitis C infection, and for Crohn's Disease. In addition, it operates a regional clinical reference laboratory that provides diagnostic services to the greater New York and New Jersey medical community. This laboratory offers a menu of routine and esoteric clinical laboratory tests or procedures. These tests are frequently used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. Enzo Biochem markets its products and services through direct sales, manufacturers, and distributors. The company was co-founded by Elazar Rabbani, Shahram K. Rabbani, and Barry W. Weiner in 1976. Enzo Biochem is headquartered in Farmingdale, New York.
